CSPAM
TEVA icon

Cary Street Partners Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Cary Street Partners Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-50
Closed -$443 – 376
2023
Q1 		$443 Hold
50
– – ﹤0.01% 390
2022
Q4 		$456 Hold
50
– – ﹤0.01% 435
2022
Q3 		$0 Buy
+50
New +$442 ﹤0.01% 416

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cary Street Partners Asset Management's TEVA Position: Q2 2023 in Review

Cary Street Partners Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2023, closing a stake of 50 shares — an estimated $443 sold.

Cary Street Partners Asset Management first reported a position in TEVA in Q3 2022 and held it in 3 quarters. The position peaked at $456 in Q4 2022. 428 funds tracked by Wall St. Rank hold TEVA as of Q2 2023.

  • Cary Street Partners Asset Management reported no remaining Teva Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Cary Street Partners Asset Management sold 50 Teva Pharmaceuticals shares in Q2 2023, an estimated $443.
  • Cary Street Partners Asset Management first reported a position in Teva Pharmaceuticals in Q3 2022 and held it in 3 quarters.
  • Cary Street Partners Asset Management's Teva Pharmaceuticals position peaked at $456 in Q4 2022.
  • 428 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2023.

Based on Cary Street Partners Asset Management's 13F filing for Q2 2023, filed 10 Aug 2023.